生物标记物指导晚期非小细胞肺癌治疗的研究进展
Research progress of biomarker for advanced non-small cell lung cancer
摘要
肺癌无论是发病率和死亡率均居首位，非小细胞肺癌（non-small cell lung cancer, NSCLC）占肺癌的80％，且一旦发现80％属于晚期。以铂类为基础的药物联合化疗，中位生存期（median surviual time, MST）可达10个月，然而，化疗疗效已经达到了平台期。为进一步增加疗效并降低毒性，以肿瘤的分子特点为基础的个体化治疗越来越受到重视，现就化疗和靶向药物的分子标记物以及在指导晚期非小细胞肺癌患者的个体化治疗方面的临床应用综述如下。
出处
《中华肺部疾病杂志（电子版）》
CAS
2011年第5期59-62,共4页
Chinese Journal of Lung Diseases(Electronic Edition)
参考文献33
-
1Kawano O,Sasaki H,Endo K,et al.PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer . 2006
-
2Kawano O,Sasaki H,Okuda K,et al.PIK3CA gene amplification in Japanese non-small cell lung cancer. Lung Cancer . 2007
-
3Testa JR,Bellacosa A.AKT plays a central role in tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America . 2001
-
4Malanga D,Scrima M,De Marco C,et al.Activating E17K mutation in the gene encoding the protein kinase AKT1in a subset of squamous cell carcinoma of the lung. Cell Cycle . 2008
-
5Cobo M,Isla D,Massuti B,et al.Customizing cisplatin based on quantitative excision repair cross-complementing1mRNA expression:a phaseⅢtrial in non-small cell lung cancer. Journal of Clinical Oncology . 2007
-
6Socinski MA.The emerging role of biomarkers in advanced non-small-cell lung cancer. Clinical Lung Cancer Journal . 2010
-
7Fukuoka M,Wu YL,Thonqprasert S,et al.Biomarker analyses and final orerall survival results from a phase III,randomized,openlabel,first-line study ofgefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small cell lung cancer in Asia (IPASS). Journal of Clinical Oncology . 2009
-
8Bang Y,Kwak EL,Shaw AT,et al.Clinical activity of the oral ALK inhibitor PF-02341066in ALK-positive patients with non-small cell cancer (NSCLC). Journal of Clinical Oncology . 2010
-
9Pao W,Girard N.New driver mutations in non-small-cell lung cancer. The Lancet Oncology . 2011
-
10Jimenez C,Jones DR,Rodríguez-Viciana P,et al.Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide3-kinase. EMBO Journal . 1998
-
1朱海鹏,胡军.三阴乳腺癌的研究进展[J].医学综述,2013,19(21):3885-3887. 被引量：8
-
2胡刚,湛汇,胡如进.新辅助化疗方案在乳腺癌治疗中的应用效果观察[J].现代诊断与治疗,2014,25(22):5192-5193. 被引量：1
-
3寇光,陈颖兰,刘震天.吉非替尼治疗晚期非小细胞肺癌的临床观察[J].实用癌症杂志,2009,24(6):652-653. 被引量：3
-
4阮二宝,程毓倩.存活30月以上恶性组织细胞病4例分析[J].天津医学院学报,1994,18(4):36-38.
-
5奉水东,谭红专.肺癌EGFR基因突变检测方法的研究进展[J].中国肺癌杂志,2008,11(3):462-464. 被引量：14
-
6任婕,赵厚育,黄林.顺铂联合化疗对60例晚期上皮性卵巢癌的疗效观察[J].贵州医药,2006,30(1):45-47. 被引量：2
-
7王孟昭,张紫萱.肺癌的靶向治疗[J].第三军医大学学报,2012,34(20):2035-2038. 被引量：3
-
8王湘辉.胃癌肝转移的治疗策略[J].现代肿瘤医学,2011,19(5):1009-1011. 被引量：5
-
9王鑫,支修益.晚期非小细胞肺癌组织中ERCC1、RRM1表达水平与含铂治疗方案疗效及预后相关性分析[J].解剖与临床,2013(3):186-190. 被引量：2
-
10赵倩倩,袁天娇,吴芳君,韩玉秀,李颖.胃癌肝转移治疗方案的临床研究进展[J].大家健康（学术版）,2016(12).
